NEW YORK, Sept. 1, 2020 /PRNewswire/ --

WeissLaw LLP (PRNewsfoto/WeissLaw LLP)

If you own shares in any of the companies listed above and
would like to discuss our investigations or have any questions concerning
this notice or your rights or interests, please contact:

Joshua Rubin, Esq.
WeissLaw LLP
1500 Broadway, 16th Floor
New York, NY  10036
(212) 682-3025
(888) 593-4771
stockinfo@weisslawllp.com

Jernigan Capital, Inc. (NYSE: JCAP)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Jernigan Capital, Inc. (NYSE: JCAP) in connection with the proposed acquisition of the company by an affiliate of NexPoint Advisors, L.P.  Under the terms of the acquisition agreement, holders of JCAP's common stock will receive $17.30 in cash for each share of JCAP common stock that they own, while holders of the company's Series B Preferred stock will receive $25.00 in cash per Series B share, nearly $8.00 per share more than common shareholders.  If you own JCAP shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: http://www.weisslawllp.com/jernigan-capital-inc/

Momenta Pharmaceuticals, Inc.

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Momenta Pharmaceuticals, Inc. in connection with the proposed acquisition of the company by Johnson & Johnson.  Under the terms of the acquisition agreement, which is structured as a tender offer, MNTA shareholders will receive $52.50 in cash for each share of MNTA common stock that they own.  If you own MNTA shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: http://www.weisslawllp.com/momenta-pharmaceuticals-inc/

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/weisslaw-llp-reminds-jcap-and-mnta-shareholders-about-its-ongoing-investigations-301122492.html

SOURCE WeissLaw LLP